Porcine circovirus type 2 Cap protein and thymosin alpha1 fusion protein and application

Abstract

The invention relates to a porcine circovirus type 2 Cap protein, thymosin alpha1 fusion protein and an application, and an amino acid sequence of the fusion protein is shown as SEQ ID NO:1. The fusion protein can be used for preparing porcine circovirus type 2 subunit vaccine. The screened porcine circovirus type 2 Cap protein and a thymosin alpha1 gene having immunological enhancement effect are connected through a Lingker sequence to obtain the fusion protein. The genetic engineering subunit vaccine of the invention has good immunogenicity, and the immune response of piglet can be caused with high efficiency.

Description

technical field [0001] The invention belongs to the field of biotechnology, in particular to a fusion protein of porcine circovirus type 2 Cap protein and thymosin α1 and its application. Background technique [0002] Porcine Circovirus type 2 (PCV2) is the causative agent of Postweaning multsystemic wasting syndrome (PMWS), which causes progressive emaciation, cough, dyspnea, diarrhea, and pale skin in weaned piglets Or symptoms such as yellow staining, swollen lymph nodes, and gray-white edema of the kidneys. At the same time, the disease can also cause a certain degree of immunosuppression, which can easily cause secondary or concurrent infections of other diseases. Since clinical porcine circovirus was first discovered in Canada in 1991, the disease has caused huge economic losses to the swine industry all over the world. The Cap protein encoded by the ORF2 gene of porcine circovirus type 2 is the main structural protein of PCV2, which can self-assemble into viral part...

AI Technical Summary

Problems solved by technology

[0004] Although thymosin αl has broad application prospects, because its gene is too short, it is difficult to use genetic engineering methods to achieve direct expression, so most of them are che...

Images